A Phase 3 interventional study of Masitinib and Placebo in Asthma, sponsored by AB Science. Completed at 5 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-08.
Sponsored by AB Science · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Asthma with a site in Argentina — 16 open to participants now, 25 under way, 12 of them phase 3. Asthma · Argentina.
Among the 147 studies in Asthma with a site in Argentina, this one is the 92nd largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2016, is one of 82 in phase 3, and was the 93rd registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →16 of the 147 studies in Asthma with a site in Argentina are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Argentina, United States, China and 2 more countries
Ages 18–85
GlaxoSmithKline · Sites in Argentina, United States, Canada and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in Argentina, France, Germany and 7 more countries
Ages 12–17
AstraZeneca · Sites in Argentina, United States, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in Argentina, United States, Czechia and 4 more countries
Ages 4–11
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 347 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 517 across the 141 interventional studies, 697 across the 6 observational. Of the 122 that completed or were terminated, 88 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
146 of 147 have an industry lead sponsor. The 10 most frequent:
AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
AB Science has 3 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
12 of the studies in Asthma with a site in Argentina that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
Add all 12 to your calendar (.ics) → With an account.
Among the 147 studies in Asthma with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels.
Masitinib is a selective tyrosine kinase inhibitor. It is known that activation of inflammatory cells, such as mast cells, and fibrous tissue remodeling are associated with c-Kit, Lyn and PDGFR kinase signaling pathways; all key targets of masitinib. This is a multicenter, double-blind, randomized, parallel-group (ascending dose titration of masitinib to 6.0 mg/kg/day and matching placebo), comparative study of oral masitinib in the treatment of patients with severe asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels. Eligible patients will be treated during at least 48 weeks.
Main inclusion criteria include:
Main exclusion criteria include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
Drug: Masitinib
Participants receive matched placebo
Drug: Placebo
Also known as: AB1010
Also known as: Placebo Oral Tablet
Severe asthma exacerbation rate
The number of severe asthma exacerbations over time frame of outcome measure
Time frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months
Asthma exacerbation rate
The number of asthma exacerbations over time frame of outcome measure
Time frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months
Asthma Control Questionnaire (ACQ)
Asthma Control Questionnaire (ACQ) * Type of questionnaire-description: A simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment. * Number of items: 7 items; 1 week recall (for items on symptoms and rescue inhaler use) * Number of domains \& categories: ACQ has a multidimensional construct assessing symptoms (5 items--self-administred) and rescue inbronchodilator use (1 item-self-administered), and FEV1% (1 item) completed by clinic staff * Scaling of items: 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use; and 7 categories for FEV1%). Scores range between 0 (totally controlled) and 6 (severely uncontrolled).
Time frame: 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2016 to primary completion in Sep 2020, 45 months.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 45 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Masitinib